Answer
Fever (pyrexia) and rash are uncommon with NovoSeven (eptacog alfa), reported at frequencies of 1 in 1,000 to fewer than 1 in 100 overall; in acquired haemophilia trials, pyrexia and erythematous rash were reported in 1% of treatment episodes.
Sources for this answer
- NovoSeven 2mg (100 KIU) powder and solvent for solution for injectionNovo Nordisk Limited · emc · SmPC §4.8 Undesirable effects · Version 2Document updated
Sources checked